Gene Insertion - Pluripotent Stem Cells 2012-2017

The Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Gene Insertion - Pluripotent Stem Cells, awarded by the National Institutes of Health (NIH) Center for Regenerative Medicine (NIH-CRM), focuses on advancing stem cell technology research. The contract supports the NIH intramural Research Program by procuring stem cell lines and developing critical protocols and standard operating procedures for deriving, culturing, and differentiating stem cells. This vehicle enables the NIH to access specialized scientific services and support for cutting-edge regenerative medicine research through multiple prime contractors.

The task orders under this IDIQ demonstrate a range of professional support services related to stem cell research, with contract values typically between $435,882 and $1,001,068. Contractors include Xcell Science Incorporated (a minority-owned, woman-owned small business), Lonza Walkersville, Inc., and Cellectis Bioresearch Inc. The delivery orders have performance periods ranging from less than a year to approximately five years, with most ultimate completion dates between 2014 and 2017. While most task orders had no specific small business set-aside, one contract was explicitly set aside for small businesses. The work is predominantly performed in locations such as Novato, California, and the funding consistently comes from the National Heart, Lung and Blood Institute (NHLBI), with all task orders utilizing a firm-fixed-price pricing structure.